GSH-conjugation Reduces PGV-1 Cytotoxicity and Its Ability in Downregulating N-Myc, β-catenin, and p62 Protein in Huh-6 Cells
Abstract
BACKGROUND: Pentagamuvone-1 (PGV-1), a synthetic curcumin analogue, exhibits potent anticancer activity against Hepatocellular Carcinoma (HCC) by disrupting cell cycle regulation and downregulating key oncogenes such as N-Myc. Numerous studies have examined the role of glutathione (GSH) conjugation in modulating the anticancer properties of curcumin and its analogues. In contrast, the impact of PGV-1 metabolism, particularly GSH conjugation, and its implications for anticancer efficacy have not yet been elucidated. This study was performed to prepare GSH-conjugated PGV-1 (PGV-1-(GSH)2) as the model of PGV-1 metabolite and evaluate its potential distinct cytotoxicity on Huh-6 cells.
METHODS: PGV-1 was synthesized via an acid-catalyzed reaction between 4-hydroxy-3,5-dimethylbenzaldehyde and cyclopentanone while PGV-1-(GSH)2 was obtained through reflux at 70oC for 2 hours. The cytotoxic effects of PGV-1 and PGV-1-(GSH)2 on Huh-6 and JHH4, two HCC cells, were assessed using a cell counting kit-8 (CCK-8) assay, while immunoblotting was performed to evaluate their impact on N-Myc and its downstream protein such as β-catenin, and p62.
RESULTS: PGV-1-(GSH)2 was prepared through GSH conjugation of PGV-1 in orange color solution, as confirmed by Electrospray Ionization Mass Spectrometry (ESI-MS), Fourier Transform Infrared Spectroscopy (FT-IR), and Nuclear Magnetic Resonance (NMR) analysis. Cytotoxicity assays revealed that PGV-1-(GSH)2 exhibited less potent anticancer activity against HCC cells than PGV-1. GSH conjugation also decreased the ability of PGV-1 in downregulating the N-Myc, β-catenin, and p62 protein level.
CONCLUSION: The prepared PGV-1-(GSH)2 reduces the cytotoxicity of PGV-1 and its ability on downregulating N-Myc, β-catenin, and p62 in Huh-6 cells. These findings highlight the need for further exploration about the study of PGV-1 metabolism which could affect the anticancer efficacy against HCC.
KEYWORDS: curcumin, PGV-1, GSH, HCC, N-Myc
Full Text:
PDFReferences
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49, CrossRef.
Deng Y, Verron E, Rohanizadeh R. Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Anticancer Res. 2016; 36(11): 5639-47, CrossRef.
Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011; 10: 12, CrossRef.
Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 2019; 20(5): 1033, CrossRef.
Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015; 35(2): 645-51, PMID.
Mock CD, Jordan BC, Selvam C. Recent advances of curcumin and its analogues in breast cancer prevention and treatment. RSC Adv. 2015; 5(92): 75575-88, CrossRef.
Novitasari D, Kato JY, Ikawati M, Putri DDP, Wulandari F, Widyarini S, et al. PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced rats. J App Pharm Sci. 2023; 13,(8): 204-11, CrossRef.
Moordiani M, Novitasari D, Susidarti RA, Ikawati M, Kato JY, Hippo Y, et al. Pentagamavunone-1 suppresses MYCN-positive HuH-7 cancer cell growth via mitotic arrest in vitro. Indones J Pharm. 2024; 35(4): 649-59, CrossRef.
Moordiani M, Novitasari D, Susidarti RA, Ikawati M, Kato JY, Meiyanto E. Curcumin analogs PGV-1 and CCA-1.1 induce cell cycle arrest in human hepatocellular carcinoma cells with overexpressed MYCN. Indones Biomed J. 2023; 15(2): 141-9, CrossRef.
Nugraheni N, Zulfin UM, Lestari B, Hapsari NP, Ikawati M, Utomo RY, et al. PGV-1 causes disarrangement of spindle microtubule organization resulting in aberrant mitosis in HLF and HuH6 cells associated with altered MYCN status. Adv Pharm Bull. 2024; 14(3): 665-74, CrossRef.
Ikawati M, Utomo RY, Hapsari NP, Meiyanto E, Oka C. Diosmin enhances the anti-migration activity of curcumin analog PGV-1 on colorectal cancer cells. Indones Biomed J. 2024; 16(1): 56-65, CrossRef.
Novitasari D, Nakamae I, Yoneda-Kato N, Kato JY, Hippo Y, Suenaga Y, et al. The combination of sorafenib and PGV-1 inhibits the proliferation of hepatocellular carcinoma through c-myc suppression in an additive manner: in vitro studies. Adv Pharmacol Pharm Sci. 2024; 2024: 4297953, CrossRef.
Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T, et al. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep. 2019; 9(1): 1-12, CrossRef.
Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. Adv Pharm Bull. 2019; 9(3): 445-52, CrossRef.
Meiyanto E, Putri DDP, Susidarti RA, Murwanti R, Sardjiman S, Fitriasari A, et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 2014; 15(1): 179-84, CrossRef.
Wang Y, Gao S, Wang W, Xia Y, Liang J. Downregulation of n‑myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2018; 18(1): 377-84, CrossRef.
Gan L, Ren Y, Lu J, Ma J, Shen X, Zhuang Z. Synergistic effect of 3-bromopyruvate in combination with rapamycin impacted neuroblastoma metabolism by inhibiting autophagy. Onco Targets Ther. 2020; 13: 11125-37, CrossRef.
Zhong SJ, Xing YD, Dong LY, Chen Y, Liu N, Wang ZM, et al. Progress in the study of curcumin metabolism in vivo. J. Asian Nat. Prod. Res. 2025; 27(5): 639-57, CrossRef.
Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. BioFactors. 2013; 39(1): 14-20, CrossRef.
Awasthi S, Pandya U, Singhal SS, Lin JT, Thiviyanathan V, Seifert WE, et al. Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1. Chem Biol Interact. 2000; 128(1): 19-38, CrossRef.
Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018; 8(1): 2039, CrossRef.
Jusup I, Batubara L, Ngestiningsih D, Fulyani F, Paveta DA, Bancin PTLA. Association between malondialdehyde, GSH/GSSG ratio and bone mineral density in postmenopausal women. Mol Cell Biomed Sci. 2021; 5(1): 13-7, CrossRef.
Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, Chen L, et al. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J. 2001; 15(1): 19-21, CrossRef.
Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013: 2013: 972913, CrossRef.
Debele TA, Wu HC, Wu SR, Shan YS, Su WP. Combination delivery of alpha-tocopheryl succinate and curcumin using a GSH-sensitive micelle (PAH-SS-PLGA) to treat pancreatic cancer. Pharmaceutics. 2020; 12(8): 778, CrossRef.
Usta M, Wortelboer HM, Vervoort J, Boersma MG, Rietjens IMCM, van Bladeren PJ, et al. Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells. Chem Res Toxicol. 2007; 20(12): 1895-902, CrossRef.
Sardjiman SS, Reksohadiprodjo MS, Hakim L, van der Goot H, Timmerman H. 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur J Med Chem. 1997; 32(7): 625-30, CrossRef.
Sun A, Lu YJ, Hu H, Shoji M, Liotta DC, Snyder JP. Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett. 2009; 19(23): 6627-31, CrossRef.
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64(4): 353-6, CrossRef.
Zhou T, Ye L, Bai Y, Sun A, Cox B, Liu D, et al. Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: A novel curcumin analog. PLoS One. 2014; 9(9): e107876, CrossRef.
Wulandari F, Ikawati M, Kirihata M, Kato JY, Meiyanto E. Curcumin analogs, PGV-1 and CCA-1.1 exhibit anti-migratory effects and suppress MMP9 expression on WiDr cells. Indones Biomed J. 2021; 13(3): 271-80, CrossRef.
Utomo RY, Wulandari F, Novitasari D, Lestari B, Susidarti RA, Jenie RI, et al. Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties. Adv Pharm Bull. 2021; 12(3): 603-12, CrossRef.
Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018; 217(7): 2291-8, CrossRef.
Rahmawati DY, Dwifulqi H, Sandra F. Origin, stemness, marker and signaling pathway of oral cancer stem cell. Mol Cell Biomed Sci. 2020; 4(3): 100-4, CrossRef.
Qin XY, Suzuki H, Honda M, Okada H, Kaneko S, Inoue I, et al. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci USA. 2018; 115(19): 4969-74, CrossRef.
Schläfli AM, Adams O, Galván JA, Gugger M, Savic S, Bubendorf L, et al. Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget. 2016; 7(26): 39544-55, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i4.3634
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
